EA201990230A1 - Белки, связывающие лиганд 1 запрограммированной смерти 1 (pd-l1), и способы их использования - Google Patents

Белки, связывающие лиганд 1 запрограммированной смерти 1 (pd-l1), и способы их использования

Info

Publication number
EA201990230A1
EA201990230A1 EA201990230A EA201990230A EA201990230A1 EA 201990230 A1 EA201990230 A1 EA 201990230A1 EA 201990230 A EA201990230 A EA 201990230A EA 201990230 A EA201990230 A EA 201990230A EA 201990230 A1 EA201990230 A1 EA 201990230A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
programmed death
protein binding
binding ligand
contain
Prior art date
Application number
EA201990230A
Other languages
English (en)
Inventor
Брайан Рабинович
Наталия Мартин-Ороско
Ласло Радваньи
Original Assignee
Айовэнс Байотерапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айовэнс Байотерапьютикс, Инк. filed Critical Айовэнс Байотерапьютикс, Инк.
Publication of EA201990230A1 publication Critical patent/EA201990230A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящая заявка предусматривает белки, такие как антитела, которые содержат антигенсвязывающую часть, которая специфически связывается с лигандом 1 запрограммированной смерти 1 (PD-L1). Также предусмотрены нуклеиновые кислоты, кодирующие белки, и клетки (например, генетически модифицированные цитотоксические лимфоциты), которые содержат такие нуклеиновые кислоты. В некоторых вариантах осуществления рассматриваемый способ включает снижение взаимодействия между PD-L1 на первой клетке и PD-1 на второй клетке. В некоторых случаях контакт происходит in vivo. Например, предоставленные способы и композиции можно использовать при лечении вирусной инфекции и злокачественной опухоли, таком как лечение солидных опухолей через ACT или через введение рассматриваемого белка, который специфически связывается с PD-L1.
EA201990230A 2016-07-07 2017-07-07 Белки, связывающие лиганд 1 запрограммированной смерти 1 (pd-l1), и способы их использования EA201990230A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662359612P 2016-07-07 2016-07-07
PCT/US2017/041241 WO2018009894A1 (en) 2016-07-07 2017-07-07 Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
EA201990230A1 true EA201990230A1 (ru) 2019-07-31

Family

ID=59366537

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990230A EA201990230A1 (ru) 2016-07-07 2017-07-07 Белки, связывающие лиганд 1 запрограммированной смерти 1 (pd-l1), и способы их использования

Country Status (15)

Country Link
US (2) US11141434B2 (ru)
EP (1) EP3481867B1 (ru)
JP (1) JP7093771B2 (ru)
KR (1) KR102630017B1 (ru)
CN (1) CN109843921B (ru)
AU (1) AU2017292889B2 (ru)
BR (1) BR112019000185A2 (ru)
CA (1) CA3030156A1 (ru)
EA (1) EA201990230A1 (ru)
IL (1) IL264104B2 (ru)
MA (1) MA45595A (ru)
MX (1) MX2019000149A (ru)
NZ (1) NZ750005A (ru)
SG (1) SG11201900138TA (ru)
WO (1) WO2018009894A1 (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
WO2017123981A1 (en) * 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunologic treatment of cancer
KR102171496B1 (ko) 2013-12-05 2020-10-30 알에프이엠비 홀딩스, 엘엘씨 면역 요법을 위한 보조 메커니즘으로서의 고주파 전기막 파괴(rf-emb)에 의한 암 항원의 항원표출세포로의 개선된 표출 시스템
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US11141216B2 (en) 2015-01-30 2021-10-12 Immunsys, Inc. Radio-frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US10166255B2 (en) 2015-07-31 2019-01-01 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
JP7181862B2 (ja) * 2016-10-18 2022-12-01 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 腫瘍浸潤リンパ球および治療の方法
CN110494543A (zh) 2016-10-19 2019-11-22 弗洛设计声能学公司 通过声学的亲和细胞提取
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
AU2018278327B2 (en) 2017-06-01 2023-03-16 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies and methods of use thereof
WO2019118921A1 (en) 2017-12-14 2019-06-20 Flodesign Sonics, Inc. Acoustic transducer drive and controller
BR112020018658A2 (pt) 2018-03-15 2020-12-29 KSQ Therapeutics, Inc. Composições de regulação gênica e métodos para imu-noterapia aprimorada
MX2022007598A (es) 2019-12-20 2022-09-23 Instil Bio Uk Ltd Dispositivos y métodos para el aislamiento de linfocitos infiltrantes de tumores y usos de los mismos.
WO2024040138A1 (en) 2022-08-17 2024-02-22 Purdue Research Foundation Universal natural killer cells derived from human pluripotent stem cells and method of use
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
JP2004534721A (ja) 2000-10-31 2004-11-18 ピーアール ファーマシューティカルズ，インク． 生理活性分子の向上した送達のための方法及び組成物
WO2004021995A2 (en) 2002-09-06 2004-03-18 The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
AU2004280623B2 (en) 2003-10-08 2010-12-02 Wilson Wolf Manufacturing, LLC Cell culture methods and devices utilizing gas permeable materials
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
CN101104640A (zh) * 2006-07-10 2008-01-16 苏州大学 抗人pd-l1单克隆抗体制备及应用
SI2342226T1 (sl) * 2008-09-26 2016-11-30 Dana-Farber Cancer Institute Inc. Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
AU2010241864B2 (en) 2009-04-30 2014-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
SG181559A1 (en) 2009-12-08 2012-07-30 Wolf Wilson Mfg Corp Improved methods of cell culture for adoptive cell therapy
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
RS61854B1 (sr) 2010-11-12 2021-06-30 Nektar Therapeutics Konjugati il-2 dela i polimera
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
EP2768939B1 (en) 2011-10-21 2016-08-17 Cell Medica Limited Device for the aseptic expansion of cells
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
CA2872504A1 (en) 2012-05-18 2013-11-21 Wilson Wolf Manufacturing Corporation A static animal cell culture and cell recovery
JP2015519080A (ja) 2012-06-11 2015-07-09 ウィルソン ウォルフ マニュファクチャリング コーポレイションＷｉｌｓｏｎ Ｗｏｌｆ Ｍａｎｕｆａｃｔｕｒｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ 養子細胞療法のための改良型細胞培養方法
CA2902448C (en) 2013-03-01 2023-04-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor reactive t cells from peripheral blood
ES2859678T3 (es) 2013-03-01 2021-10-04 Us Health Métodos para producir poblaciones enriquecidas de células T reactivas a tumores a partir de un tumor
CN103242448B (zh) * 2013-05-27 2015-01-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用
CN110564612B (zh) 2013-06-24 2024-07-02 威尔逊沃夫制造公司 用于透气性细胞培养过程的封闭系统装置和方法
US10233425B2 (en) 2013-09-16 2019-03-19 The Trustees Of The University Of Pennsylvania CD137 enrichment for efficient tumor infiltrating lymphocyte selection
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
ES2776407T3 (es) 2014-03-20 2020-07-30 H Lee Moffitt Cancer Ct & Res Linfocitos infiltrantes de tumor para terapia celular adoptiva
WO2015157636A1 (en) 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
MY180750A (en) 2014-06-11 2020-12-08 Polybiocept Ab Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
PL3193931T3 (pl) 2014-09-16 2021-03-08 Innate Pharma Neutralizacja szlaków inhibitorowych w limfocytach
WO2016053338A1 (en) 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
EP3034092A1 (en) 2014-12-17 2016-06-22 Université de Lausanne Adoptive immunotherapy for treating cancer
KR20170090506A (ko) 2014-12-19 2017-08-07 다나-파버 캔서 인스티튜트 인크. 키메라 항원 수용체 및 이의 사용 방법
MD3532607T2 (ro) 2016-10-26 2024-07-31 Iovance Biotherapeutics Inc Restimularea limfocitelor infiltrante în tumori crioconservate
WO2018129332A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
EP3622055A1 (en) 2017-05-10 2020-03-18 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
EP3635097A1 (en) 2017-06-05 2020-04-15 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma

Also Published As

Publication number Publication date
IL264104A (en) 2019-01-31
WO2018009894A1 (en) 2018-01-11
IL264104B1 (en) 2024-04-01
KR102630017B1 (ko) 2024-01-25
EP3481867A1 (en) 2019-05-15
EP3481867B1 (en) 2024-09-04
MX2019000149A (es) 2019-09-23
US20190298770A1 (en) 2019-10-03
CN109843921A (zh) 2019-06-04
KR20190038825A (ko) 2019-04-09
CA3030156A1 (en) 2018-01-11
AU2017292889A1 (en) 2019-02-14
JP2019525771A (ja) 2019-09-12
JP7093771B2 (ja) 2022-06-30
MA45595A (fr) 2019-05-15
CN109843921B (zh) 2023-05-26
US12023355B2 (en) 2024-07-02
NZ750005A (en) 2023-06-30
US11141434B2 (en) 2021-10-12
BR112019000185A2 (pt) 2019-04-16
SG11201900138TA (en) 2019-02-27
AU2017292889B2 (en) 2024-09-12
US20220025052A1 (en) 2022-01-27
IL264104B2 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
EA201990230A1 (ru) Белки, связывающие лиганд 1 запрограммированной смерти 1 (pd-l1), и способы их использования
SA522432917B1 (ar) ميوتينات إنترليوكين-21 وطرق العلاج
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
MA41393A1 (fr) Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers
WO2018187613A3 (en) Anti-icos agonist antibodies and uses thereof
MA46648A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers
MA43490A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers
MA41520B2 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MA46508A1 (fr) Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers
EA201790986A1 (ru) Антитела к cd73 и их применения
MA42294A (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
MX2021011330A (es) Anticuerpos de claudina-6 y conjugados de fármacos.
MX2024003355A (es) Anticuerpos anti-cd3.
EA202090431A1 (ru) Мутеины интерлейкина-21 и способы лечения
EA202091596A1 (ru) Антитела к pd-1 и способы лечения
EA202092928A1 (ru) Dll3-cd3 биспецифические антитела
EA202190465A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нхл и других видов рака
EA202092560A3 (ru) Новые пептиды и комбинации пептидов и каркасы для применения в иммунотерапии почечноклеточной карциномы (пкк) и других видов рака